Merck returns drug rights to AVEO

Portfolio prioritization has caused Merck to return AV-299, an anti-hepatocyte growth factor antibody drug, to AVEO Pharmaceuticals. In June the developer initiated a Phase II trial of the drug, which triggered an $8.5 million milestone payment from Merck. Top-line efficacy data from the AV-299 Phase II trial are expected in late 2011. Release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.